source
- FDA advisory panel lifts restrictions on six wellness peptidesThe FDA's advisory committee concluded its two-day meeting by voting to remove the existing limits on six widely used health and wellness peptides. Committee members said the vote overrode earlier…
- MapLight’s schizophrenia pill hits primary endpoint but falls short of challenging BMS’s CobenfyMapLight Therapeutics reported results from its Phase 2 ZEPHYR trial of the oral muscarinic agonist ML-007C-MA in schizophrenia. The trial met its primary endpoint, showing a statistically signifi…